How effective is Seripase (BRINEURA) treatment? Real patient feedback and case sharing

Seripase (Brineura, common name: cerliponase alfa) is an enzyme replacement therapy for 2 neuronal ceroid lipofuscinosis (CLN2). CLN2is a rare childhood neurodegenerative disease caused by a deficiency of the TPP1 enzyme. The disease usually occurs in children between the ages of 2 and 4. The early symptoms mainly include reduced language ability and motor function. As the disease progresses, serious problems such as epilepsy, vision loss, and mental decline may also occur. Due to TPP1enzyme deficiency leading to lysosomal dysfunction, waste accumulation in brain cells accelerates neurodegenerative damage, ultimately seriously affecting children's quality of life and survival.

BrineuraBy supplementing the missing TPP1 enzyme, we fundamentally target the cause of the disease. Clinical data show that early use of Brineura can significantly slow the deterioration of motor and language skills in children with CLN2. In pivotal clinical trials, most children who received Brineura showed stable motor scores with no significant decline in motor scores from 48 to 96 weeks of follow-up, demonstrating significant improvement compared with untreated natural history controls. This shows that Brineura can delay the progression of the disease to a certain extent, especially in terms of children's daily activities, maintain their ability to take care of themselves, and reduce the burden on the family.

Real clinical feedback from patients also shows the real value ofBrineura treatment. After receiving treatment, many families report that the maintenance of children's motor ability, walking, balance and fine hand movements has been significantly improved or stabilized compared to before, and the loss of language expression skills has also been slowed down. Although Brineura cannot be completely cured CLN2, with continued supplementation of the TPP1 enzyme, children can slow the progression of the disease, providing them with more time to participate in daily life and educational activities. This effect was particularly significant in patients who were diagnosed early and started treatment as early as possible, highlighting the importance of early intervention.

However,Treatment of Brineura is not without its challenges. The drug must be administered by intracerebroventricular infusion, once every two weeks, and each session lasts approximately 4 to 5 hours, which is a large treatment burden for children and families. In addition, side effects such as fever, headache, seizures, and hypotension may occur during the infusion process, and the intraventricular infusion device may also cause infection or mechanical failure. Therefore, during the treatment process, it must be carried out under the guidance of a professional medical team, the patient's neurological function and physical condition must be regularly monitored, and preventive and response measures must be taken to ensure the safety and effectiveness of the treatment.

In the long term, Brineura offers CLN2 patients hope of changing the natural course of the disease. Although a complete cure is still lacking, delaying the course of the disease through enzyme replacement therapy can significantly improve the quality of life of children and the psychological stress of families. At the same time, this also provides an important reference for the development of rare disease drugs and promotes research on precision treatments for rare neurodegenerative diseases. In the future, with the accumulation of treatment experience, optimization of dosage forms and the development of related adjuvant therapies, the clinical application prospects of Brineura are expected to be further expanded, bringing good news to more patients.

Taken together, seripase (Brineura) is an important breakthrough in the current CLN2 treatment field. It effectively slows down the decline of children's neurological function through the enzyme replacement mechanism targeting the cause. Real clinical feedback shows that the patient's movement and language abilities can be maintained within a certain period of time. Despite issues such as complex infusion procedures, potential side effects, and high costs, Brineura provides irreplaceable therapeutic value and quality-of-life opportunities for children diagnosed early. Parents and the medical team need to work closely together to scientifically formulate treatment plans to maximize the clinical benefits of Brineura.

Reference materials:https://www.drugs.com/